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The global use of a capsular polysaccharide-based pneumococcal vaccine has been limited because of
serotype-specific protection and poor effectiveness in individuals with low immunocompetency. The mucosal
immune system develops earlier in infants and lasts longer in the elderly than does the systemic immune
system. Furthermore, mucosal immunization is beneficial for AIDS patients, because human immunodefi-
ciency virus-infected subjects can develop normal mucosal antibody responses even in late clinical phases. For
these reasons, we evaluated recombinant pneumococcal surface adhesin A (rPsaA) of Streptococcus pneumoniae
in terms of cross-protective immune responses after oral delivery. Encapsulated rPsaA provided higher
immunogenicity than naked rPsaA. Coencapsulation or codelivery of the cholera toxin (CT) B subunit (CTB)
and CT also increased the immunogenicity of rPsaA. Cross-protective immunities against five strains of S.
pneumoniae (types 4, 6B, 14, 19F, and 23F) were induced after oral immunization with microencapsulated
rPsaA. Lung colonization and septicemia caused by the five serotypes were significantly inhibited by oral
immunization with microencapsulated rPsaA. These results suggest that rPsaA coencapsulated with CTB can
be used as an oral vaccine to induce cross-protective immunity for the prevention of pneumococcal infection.
Streptococcus pneumoniae is an important respiratory patho-
gen that causes pneumonia, meningitis, otitis media, and bac-
teremia (9). Although polysaccharide (PS) vaccines can elicit a
protective immune response against pneumococcal infection in
adults, those have little effect in young children (2 years), in
the elderly, and in patients with immunodeficiencies, such as
AIDS (12, 18, 24, 36, 43). In efforts to overcome these limita-
tions, protein-PS conjugate vaccines are being evaluated (19,
21, 35). The conjugate PS appear to activate T-helper cells,
thereby eliciting T-cell-dependent responses that provide a
long-term immunological memory. Although protein-PS con-
jugate vaccines were effective in eliminating nasopharyngeal
carriage of vaccine serotypes, they increased carriage of non-
vaccine serotypes causing invasive disease (30). Therefore,
conjugate vaccines seem to be less effective in reducing the
overall incidence of pneumococcal disease than expected.
Pneumococcal proteins eliciting cross-protective immunity
might provide alternative approaches (34).
Several pneumococcal proteins, such as pneumolysin, neur-
aminidase, autolysin, pneumococcal surface protein A, and
pneumococcal surface adhesin A (PsaA), are known to elicit
protective immunity (1, 8, 23, 45). Recently, it has been also
reported that combinations of pneumococcal virulence pro-
teins, pneumolysin, pneumococcal surface protein A, and PsaA
can elicit enhanced protection (7, 31).
PsaA, a 37-kDa metal-binding lipoprotein, plays a critical
role in bacterial adherence to respiratory mucosa and in viru-
lence (6). Mice systemically immunized with PsaA were signif-
icantly protected against heterologous challenge with type 3
pneumococcal strain WU2 (45). Intranasal immunization of
mice with PsaA conferred resistance against nasopharyngeal
carriage (7). Immunization of humans with heat-killed bacteria
resulted in elevation of salivary antibodies to PsaA (13).
Amino acid sequences of PsaA are highly conserved within all
90 pneumococcal serotypes (13, 38). Taken together, these
findings indicate that PsaA might be useful as a vaccine which
confers cross-protective immunity against various serotypes.
The local secretory immunoglobulin A (secretory IgA) has
been shown to prevent both bacterial colonization at the mu-
cosal surfaces and spread into the systemic circulation (41).
Moreover, mucosal immunization could be a better alternative
for young children and for the elderly, since the mucosal im-
mune system develops earlier in infants and lasts longer in the
elderly compared with the systemic immune system (16, 37,
44). Mucosal immunization is also beneficial for human immu-
nodeficiency virus patients (41), because human immunodefi-
ciency virus-infected subjects can develop normal mucosal an-
tibody responses even in late clinical phases (15, 22, 29, 33).
Oral immunization has been limited because of inefficient
antigen uptake, induction of tolerance, and proteolytic degra-
dation of the antigens before they reach immune cells (42). To
overcome these limitations, numerous approaches using bio-
degradable microspheres are currently being developed (25).
The encapsulated antigens may resist digestion by gastric acid
and enzymes, be absorbed via M cells, and thus potentiate
immune responses in the common mucosal immune systems
(25, 26, 28, 32). Unlike other microspheres, water-soluble mi-
crospheres such as chitosan, starch, dextran, and alginate can
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be prepared easily in aqueous solutions at room temperature
and therefore are very useful in encapsulating antigens (4, 17,
20, 39). Especially, small alginate microspheres were consid-
ered to be an efficient carrier of antigens to the Payer’s patches
and through the lymphatic system (40).
In this study, we have evaluated whether the oral adminis-
tration of a recombinant PsaA (rPsaA) encapsulated in algi-
nate microspheres induces mucosal as well as systemic immune
responses and whether oral immunization confers to mice
cross-protective immunity against respiratory infection by S.
pneumoniae serotypes 4, 6B, 14, 19F, and 23F.
MATERIALS AND METHODS
Mice. Female BALB/c mice, 6 to 8 weeks old, were purchased from DAEHAN
Laboratory Animal Research Center Co. (Seoul, Korea) and were maintained in
the facility under standard specific-pathogen-free conditions. All mice were pro-
vided sterile food and water ad libitum and were fasted for 4 h before immuni-
zation.
Antigens. A DNA fragment (877 bp) carrying the functional psaA gene (i.e.,
without its signal sequence) was amplified by PCR from S. pneumoniae type 19F
(American Type Culture Collection, Manassas, Va.) genomic DNA. The sense
primer sequence was 5-TCACCATGGTAGCATGTGCTAGCGG-3. An NcoI
site (underlined) was introduced. The reverse primer, complementary to the 3
sequence, 5-TGCCAATCCTTCAGCAATCTTGTC A-3, had a SmaI site. The
PCR fragment was then digested with NcoI and SmaI, purified after agarose gel
electrophoresis, and ligated with the intein sequence in the expression plasmid
pCYB4 (New England Biolabs, Inc., Beverly, Mass.). The pCYB4 DNA was
digested with NcoI and SmaI and was ligated with the psaA DNA fragment.
Escherichia coli competent cells (XL1-Blue) were transformed with a recombi-
nant plasmid containing a functional psaA gene. To identify E. coli clones ex-
pressing PsaA, several colonies were screened by Western blot analysis using
polyclonal sera (1:100 dilution) from rabbits immunized with S. pneumoniae. One
stable recombinant clone (designated pCA77) expressing chimeric PsaA was
selected for further studies.
The DNA sequence of the cloned psaA was determined using an ABI PRISM
dye terminator cycle sequencing kit (Applied Biosystems, Foster City, Calif.)
with primers compatible with the Ptac promoter sequence or the intein sequence
(New England Biolabs, Inc.). The products were analyzed with a DNA sequencer
(model 373; Applied Biosystems).
The purification of rPsaA was performed as described by the manufacturer
(New England Biolabs, Inc.). The rPsaA was eluted with column buffer. The
purified rPsaA was concentrated with an Amicon Centriprep (molecular mass
cutoff, 10 kDa) and dialyzed with the distilled water. The purity of rPsaA was also
analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and Western blotting. The Bradford assay kit was used to determine the
total rPsaA protein content.
Microencapsulation of antigens. Antigens were microencapsulated as de-
scribed earlier (10). The size and surface morphology of the microspheres were
examined using a scanning electron microscope (S-2460N; Hitachi Ltd., Tokyo,
Japan) as described previously (11). To analyze the contents of encapsulated
antigen, the microspheres were dissolved in sodium citrate buffer (0.1 M, pH 7.8)
for 3 h. The protein concentration and immunogenicity of rPsaA were evaluated
with a Bradford assay kit or by enzyme-linked immunosorbent assay (ELISA),
respectively.
Immunization. Mice were immunized orally with rPsaA (40 g) three times at
intervals of 2 weeks. Various antigen formulations were used in the immuniza-
tion. The antigen formulations were as follows: group 1, naked rPsaA (nPsaA);
group 2, microencapsulated rPsaA (ePsaA); group 3, nPsaA mixed with 5 g of
cholera toxin (CT) (nPsaA-CT); group 4, ePsaA mixed with 5 g of CT (ePsaA-
CT); group 5, nPsaA mixed with 10 g of CT B subunit (CTB) (nPsaA-CTB);
group 6, ePsaA mixed with 10 g of CTB (ePsaA-CTB); and group 7, coencap-
sulated rPsaA with CTB [e(PsaA-CTB)]. Various amounts of CTB were coen-
capsulated in fabricating e(PsaA-CTB): 1.6 g of CTB [e(PsaA-CTB)1] for
group 8, 8.4 g of CTB [e(PsaA-CTB)2] for group 9, and 20.3 g of CTB
[e(PsaA-CTB)3] for group 10. CTB was purchased from List Biologicals Labo-
ratory, Inc. (Campbell, Calif.) and was shown by supplier to contain no detect-
able CT based on the results of an ADP-ribosylation assay. Mock microspheres
or microencapsulated bovine serum albumin (eBSA) was also used for the
control experiments (group 1). Oral immunizations of mice and collections of
sera, intestinal fluid, and bronchoalveolar lavage fluid were performed as de-
scribed previously (10, 14). Blood contamination of the bronchoalveolar lavage
fluid was assessed by detecting hemoglobin at by measurement of optical density
at 575 nm. Murine blood diluted serially in PBS served as a standard. The mean
blood contamination was 4%  0.7%.
ELISA. Anti-PsaA antibodies were measured by ELISA as described previ-
ously (40). Briefly, polystyrene microtiter plates (Corning, Cambridge, Mass,)
were coated with 3.2 g of rPsaA per ml in bicarbonate coating buffer. Serum
specimens were diluted 50 times, and intestinal or bronchoalveolar lavage sam-
ples diluted twofold were used as primary antibodies. The secondary antibody
used was horseradish peroxidase-conjugated goat anti-mouse immunoglobulin
(Organon Teknika Corp., Durham, N.C.). To calibrate the specific IgA, IgG, or
IgM level, a purified respective immunoglobulin with known concentrations of
isotype served as a standard. The absorbance values of the standard immuno-
FIG. 1. Expression of fusion protein (rPsaA-intein-CBD) (A), identification of the purified rPsaA protein by SDS-PAGE (B), and Western blot
analysis (C). (A) Fusion proteins were expressed in E. coli XL1-Blue at 37, 30, 25, or 20°C. Insoluble and soluble proteins were recovered in pellets
(Œ) and supernatants (‚), respectively. The density of the fusion protein band was determined with TINA software and plotted against
temperature. od, optical density units. (B and C) After purification, the rPsaA solution was separated on 10% polyacrylamide gels (B) and probed
with sera from rabbits immunized with S. pneumoniae (C). The numbers in panel B indicate molecular masses of marker proteins. An arrow
indicates the purified rPsaA protein (35 kDa).
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globulin were determined by using sandwich ELISA. The antibody concentration
was expressed as the geometric mean.
Challenge. The mice were immunized orally three times as described above.
Protection of mice against intranasal challenge with live pneumococci was ana-
lyzed by recovering viable organisms from lungs and blood of mice immunized
with various vaccines (40). Two weeks after the last immunization, mice were
anesthetized and challenged intranasally with S. pneumoniae in 20 l of medium
as described previously (47). After 18 h, both blood and bronchoalveolar lavage
solutions were serially diluted and plated on sheep blood agar plates. Bacterial
cultures were incubated at 37°C in a 5% CO2 incubator, and colonies were
counted after 18 h. Five strains, which are components of a seven-valent poly-
saccharide vaccine, were used for challenging infection. The virulence of pneu-
mococci was enhanced by passage through mice. The challenging inocula for
each serotype were predetermined in the range showing reproducible linear
dose-response (CFU in samples) curves. After the mice were immunized orally
with e(PsaA-CTB)1, they were challenged intranasally with 2  106 CFU of
serotype 4 (ATCC 6304), 1  1010 CFU of serotype 6B (ATCC 6326), 1  109
CFU of serotype 14 (ATCC 6314), 1  106 CFU of serotype 19F (ATCC 6319),
or 1  109 CFU of serotype 23F (ATCC 6323) at 2 weeks after the last immu-
nization.
Statistics. Unpaired, one-tailed Student t tests were used to compare the mean
antibody levels and the CFU between groups of mice. The values were consid-
ered statistically significant at a P value of 0.05.
RESULTS
Expression and purification of rPsaA. We constructed a
plasmid, pCA77, expressing psaA of S. pneumoniae type 19F.
DNA sequencing revealed that the psaA sequence in the plas-
mid was identical to that of the entire authentic psaA (870 bp)
without a signal sequence. The transformed E. coli expressed a
triple fusion protein (rPsaA-intein-chitin binding domain
[CBD]). Densitometric analysis of Western blots was used to
quantitate rPsaA-intein-CBD (Fig. 1). When induced at 37°C,
most of the recombinant protein formed inclusion bodies and
was detectable in pellets. However, the fusion protein was
expressed in a soluble form that was detectable in supernatants
when induced at 20°C.
The rPsaA protein was purified by chitin affinity chromatog-
raphy. The purified 35-kDa rPsaA was characterized by SDS–
10% PAGE (Fig. 1B) and Western blotting (Fig. 1C) analysis.
The purity of rPsaA was about 90%, and the average yield was
approximately 10 mg of purified protein per liter of culture.
The purified rPsaA appeared to be soluble only in the presence
of Triton X-100 (0.1%). The purified protein formed insoluble
aggregates when more than 1.0 mg of protein per ml was
dialyzed with distilled water to prepare microspheres. For this
reason, the antigen concentration was kept below 1.0 mg/ml for
all of the procedures.
To determine whether the purified rPsaA was immunogenic,
mice were immunized with 50 g of purified rPsaA subcuta-
neously with Freund’s adjuvant. We could detect specific an-
tibody to rPsaA by ELISA (data not shown).
Microencapsulation of rPsaA. For efficient oral delivery of
rPsaA, alginate microspheres entrapping rPsaA were fabri-
cated using an interfacial gelation technique as described pre-
viously (10). The microspheres were observed by scanning
electron microscopy (Fig. 2). They had a smooth surface with-
out noticeable defects, with a diameter in the range of 0.5 to
5 m.
To quantitate rPsaA contents in ePsaA, the Bradford assay
was used. The average efficiency of the encapsulation of rPsaA
protein (100 encapsulated rPsaA/rPsaA in starting material)
was 24%. The efficiency of the encapsulation of BSA was 42%.
The percentage of rPsaA encapsulated in the microspheres
(100  weight of encapsulated rPsaA/total weight of micro-
spheres) was 0.4% (0.8% for BSA protein).
CTB in e(PsaA-CTB) was quantitated by ELISA. The
weight ratios of rPsaA to CTB were 1:0.04 in e(PsaA-CTB)1, 1:
0.2 in e(PsaA-CTB)2, and 1:0.5 in e(PsaA-CTB)3.
Antibody responses to rPsaA after oral immunization. Two
weeks after the last immunizations, the rPsaA-specific anti-
body responses were evaluated by ELISA (Table 1), and dif-
ferences were analyzed using the one-tailed Student’s t test
(Table 2). nPsaA (group 2) induced systemic and mucosal
FIG. 2. Microspheres entrapping rPsaA (ePsaA), examined using a
scanning electron microscope.
TABLE 1. Systemic and mucosal antibody responses of mice orally immunized with rPsaA
Group Vaccine No. of mice
Geometric mean concn (ng/ml)  SEM of:
Serum IgM Serum IgG Serum IgA Lung IgA Intestine IgA
1 eBSA 6 232.7  10.6 17.5  1.1 5.7  3.1 0.7 0.3 0.7  0.2
2 nPsaA 7 439.9  8.5 59.4  1.4 17.1 3.9 1.8  0.1 2.6  0.1
3 ePsaA 7 486.2  12.6 73.0  1.7 31.9 3.1 2.1  0.1 3.2  0.3
4 nPsaACT 7 466.1  23.6 72.9  5.3 29.0 3.9 2.5  0.1 3.5  0.3
5 ePsaACT 7 539.1  13.7 187.9 18.1 70.8  11.8 3.6  0.3 3.9  0.4
6 nPsaACTB 7 407.4  21.8 68.2  5.9 18.1 0.9 1.8  0.2 2.8  0.4
7 ePsaACTB 7 545.3  40.1 126.3 15.6 57.5  1.9 3.9  0.8 4.0  0.2
8 e(PsaACTB)1 7 1901.0 141.4 146.5  68.6 118.3 38.9 5.3  0.7 5.5  0.9
9 e(PsaACTB)2 7 1759.9 208.1 53.4  23.9 135.3 96.7 6.0  0.6 6.6  0.4
10 e(PsaACTB)3 9 1542.2 222.9 71.1  24.6 366.4 37.6 16.6  0.8 14.1  1.0
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antibody responses significantly (P  0.05) higher than those
induced by eBSA (group 1).
The effects of microencapsulation on the immunogenicity of
orally administered rPsaA were evaluated after the oral immu-
nization of BALB/c mice with nPsaA (group 2) or with ePsaA
(group 3). The ePsaA induced serum IgM (P  0.005), serum
IgG (P  0.001), serum IgA (P  0.006), and mucosal IgA
(P  0.03) responses that were significantly higher than those
induced by nPsaA.
To determine whether CT or CTB could enhance systemic
and mucosal immune responses against rPsaA, CT or CTB was
coadministered with vaccines. When CT was coadministered
orally with nPsaA (group 4), the rPsaA-specific serum IgG,
IgA, and mucosal IgA responses of mice significantly increased
(P  0.05). Moreover, the ePsaA-CT (group 5) induced more
prominent serum antibody and bronchoalveolar IgA responses
than those induced by ePsaA (group 3) or by nPsaA-CT (group
4) (P  0.005). Coadministration of CTB with nPsaA (group
6), however, did not show significant differences compared to
nPsaA (group 2). Mice immunized with ePsaA-CTB (group 7)
yielded higher serum IgG, IgA, and mucosal IgA responses
than those immunized with ePsaA (group 3) (P  0.05). The
systemic and mucosal antibody responses were not statistically
different between group 5 (ePsaA-CT) and group 7 (ePsaA-
CTB).
We evaluated the effects of CTB after coencapsulation with
rPsaA. All e(PsaA-CTB) elicited serum IgM, serum IgA, bron-
choalveolar IgA, and intestinal IgA responses significantly
higher than those induced by mixed ePsaA-CTB (Tables 1 and
2). The mucosal IgA responses induced by e(PsaA-CTB)3
were always higher than those induced by ePsaA-CTB (P 
0.001). On the other hand, serum IgG responses induced by
e(PsaA-CTB)3 were significantly reduced (P  0.05) com-
pared with those induced by ePsaA-CTB. e(PsaA-CTB)3,
which contains the highest concentration of CTB, induced the
most prominent mucosal IgA and serum IgA responses among
the e(PsaA-CTB) groups (P  0.01). However, serum IgG
responses induced by e(PsaA-CTB)3 were lower than those
induced by e(PsaA-CTB)1 (P  0.1).
Homotypic protection study. Mice were immunized with var-
ious formulations of antigen, and protection was evaluated by
challenge with live S. pneumoniae type 19F (Table 3). The
number of viable pneumococci recovered from the lung lavage
fluids or from the blood of mice in all groups was significantly
reduced (0.01) when compared with that of mice immunized
with mock antigen (Table 4). The extent of inhibition (EI)
[100  (1  CFUtest/CFUcontrol)] of bacterial colonization in
the bronchoalveoli or of bacteremia was analyzed. The EIs of
bacterial colonization in the lungs of mice immunized with
ePsaA, nPsaA-CTB, ePsaA-CTB, e(PsaA-CTB)1, e(PsaA-
CTB)2, and e(PsaA-CTB)3 were 85, 84, 88, 96, 95, and 86%,
respectively. Bacteremia was also inhibited, by 91, 99, 96, 100,
97, and 83%, respectively. The differences in EIs between the
groups showed no statistical significance, except for some
groups shown in Table 4. The best protection was achieved by
immunization with e(PsaA-CTB)1. Although the mucosal IgA
responses induced by e(PsaA-CTB)1 were lower than those
induced by e(PsaA-CTB)3, the mice orally immunized with
e(PsaA-CTB)1 were better protected than those immunized
with e(PsaA-CTB)3.
Heterotypic protection study. Cross-protection against chal-
lenge with five S. pneumoniae serotypes, i.e., serotypes 4, 6B,
14, 19F, and 23F, after oral vaccination was studied (Table 5).
The protection against each strain was examined by comparing
TABLE 2. Statistical significance of differences between the groups shown in Table 1.
Vaccines compared
P value for difference of antibody responses
Serum IgM Serum IgG Serum IgA Lung IgA Intestine IgA
eBSA vs nPsaA 0.05 0.05 0.05 0.05 0.05
nPsaA vs ePsaA 0.005 0.001 0.006 0.03 0.03
nPsaACT vs nPsaA NSa 0.01 0.03 0.001 0.01
ePsaACT vs ePsaA 0.01 0.001 0.005 0.005 NS
ePsaACT vs nPsaA-CT 0.01 0.001 0.005 0.005 NS
nPsaACTB vs nPsaA NS NS NS NS NS
ePsaACTB vs ePsaA NS 0.005 0.001 0.02 0.02
ePsaACTB vs ePsaA-CT NS 0.01 NS NS NS
e(PsaACTB)1 vs nPsaA-CTB 0.001 NS 0.01 0.001 0.01
e(PsaACTB)2 vs nPsaA-CTB 0.001 NS NS 0.001 0.001
e(PsaACTB)3 vs nPsaA-CTB 0.001 NS 0.001 0.001 0.001
e(PsaACTB)1 vs ePsaA-CTB 0.001 NS BSb BS BS
e(PsaACTB)2 vs ePsaA-CTB 0.001 0.01 NS 0.05 0.001
e(PsaACTB)3 vs ePsaA-CTB 0.001 0.05 0.001 0.001 0.001
e(PsaACTB)3 vs e(PsaA-CTB)1 BS BS 0.001 0.001 0.001
e(PsaACTB)3 vs e(PsaA-CTB)2 NS NS 0.01 0.001 0.001
a NS, not significant (P  0.05).
b BS, borderline significance (0.05  P  0.1).
TABLE 3. Homotypic protection of mice after oral immunization
and challenge infection with pneumococcus type 19F
Vaccine No. of mice
Concn (CFU/ml, mean  SEM)
of S. pneumoniae from:
Bronchoalveoli Blood
Mock 5 4,140 935 906  188
ePsaA 15 554 186 67  41
nPsaACTB 8 570  287 11  7
ePsaACTB 8 425  193 33  26
e(PsaACTB)1 7 140  63 3  1
e(PsaACTB)2 7 176  169 23  15
e(PsaACTB)3 9 510  255 132  79
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the number of viable pneumococci recovered from the lungs or
blood of mice immunized with mock microspheres, nPsaA-
CTB, or e(PsaA-CTB)1 (Table 5). The EIs for lung coloniza-
tion conferred by nPsaA-CTB were 100% (serotype 4), 73%
(serotype 6B), 96% (serotype 14), 84% (serotype 19F), and
100% (serotype 23F). The P values in Table 5 indicate the
statistical significances of the differences in CFU between the
test groups and the control group (mock-immunized mice).
One hundred percent means that no colonies were recovered
from lavage fluid or blood diluted 10,000-fold. The EIs for lung
colonization conferred by e(PsaA-CTB)1 were 100% (serotype
4), 100% (serotype 6B), 100% (serotype 14), 96% (serotype
19F), and 100% (serotype 23F). After immunization with
nPsaA-CTB, the bacteremia was inhibited by 100% (serotype
4), 83% (serotype 6B), 85% (serotype 14), 99% (serotype 19F),
and 88% (serotype 23F). In addition, immunization with
e(PsaA-CTB)1 conferred inhibition of bacteremia by 100%
(serotype 4), 99% (serotype 6B), 95% (serotype 14), 100%
(serotype 19F), and 100% (serotype 23F). Generally, e(PsaA-
CTB)1 provided better heterotypic protection than nPsaA-
CTB did.
DISCUSSION
The increase of drug-resistant pneumococci poses an urgent
need for new control methods. Clearly, the global prevalence
of drug-resistant pneumococci demands the development and
marketing of new vaccines, although more widespread use of
the existing 23-valent polysaccharide vaccine among high-risk
populations is essential in the interim. Immunization with a
pneumococcal vaccine is important to protect immunocompro-
mised patients from pneumonia but is often unsuccessful. A
significant breakthrough in the development of pneumococcal
vaccines would be a mucosal vaccine providing long-lasting
mucosal as well as systemic immune responses and conferring
cross-protective immunity against all of the serotypes of S.
pneumoniae.
In this study, we evaluated rPsaA in terms of mucosal and
systemic humoral immune responses as well as its ability to
induce cross-protective immunity against several serotypes of
pneumococci. Many delivery systems for oral administration of
antigens are being studied (5, 27). In this study, the prepara-
tion of rPsaA in alginate microspheres resulted in higher levels
of antigen-specific IgM, IgG, and IgA antibodies than those
produced by nPsaA in bicarbonate buffer.
Antibody responses induced by oral immunization with
rPsaA were enhanced by use of CT or CTB. Immunization
with nPsaA and CT induced both systemic and mucosal im-
mune responses significantly higher than those induced by
nPsaA without CT and comparable to the immune responses
induced by ePsaA. This finding suggests that the effect of
TABLE 4. Statistical significance of differences between
the groups of mice shown in Table 3
Vaccines compared
Significancea
Lung Blood
ePsaA vs nPsaACTB NSb NS
ePsaA vs ePsaACTB NS NS
nPsaACTB vs ePsaACTB NS NS
e(PsaACTB)1 vs nPsaACTB BSc NS
e(PsaACTB)2 vs nPsaACTB BS NS
e(PsaACTB)3 vs nPsaACTB NS BS
e(PsaACTB)1 vs ePsaACTB BS NS
e(PsaACTB)2 vs ePsaACTB NS NS
e(PsaACTB)3 vs ePsaACTB NS BS
e(PsaACTB)3 vs e(PsaACTB)1 BS BS
e(PsaACTB)3 vs e(PsaACTB)2 NS BS
a The differences between the mock-immunized mice and other groups of mice
were always statistically significant (P  0.01).
b NS, not significant (P  0.05).
c BS, borderline significance (0.05  P  0.1).
TABLE 5. Heterotypic protection of mice after oral immuization and challenge infection with various serotypes of S. pneumoniae
Pneumococcal
serotype Vaccine
CFU/ml (mean  SEM) from:
Bronchoalveoli Blood
4 Mock (4 1.6)  107 (7  0.5)  107
nPsaACTB (3  2.0)  104 (0.01)a (5  1.6)  103 (0.001)
e(PsaACTB)1 (6  1.0)  102 (0.01) (3  1.4)  103 (0.001)
6B Mock (2  0.8)  105 (4  3.0)  104
nPsaACTB (3  2.3)  104 (0.05) (3  1.8)  103 (NSb)
e(PsaACTB)1 (3  1.9)  10 (0.03) (2  1.6)  102 (BSc)
14 Mock (3 1.2)  107 (3  0.7)  103
nPsaACTB (1  0.5)  106 (0.01) (4  1.1)  102 (0.004)
e(PsaACTB)1 (8  3.6)  104 (0.01) (1  0.7)  102 (0.002)
19F Mock (4 0.9)  103 (9  1.8)  102
nPsaACTB (6  2.9)  102 (0.001) (1  0.7)  10 (0.001)
e(PsaACTB)1 (1  0.6)  102 (0.001) (3  01.8)  1 (0.001)
23F Mock (2 1.1)  108 (1  0.3)  104
nPsaACTB (3  2.4)  105 (0.04) (1  1.2)  103 (0.002)
e(PsaACTB)1 (2  1.0)  103 (0.04) (2  1.9)  10 (0.001)
a The numbers in parentheses indicate statistical significance (P value) of the difference between the mock-immunized mice and test group of mice.
b NS, not significant (P  0.1).
c BS, borderline significance (0.05  P  0.1).
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microencapsulation in enhancing immunogenicity might be
comparable to that of CT. nPsaA mixed with CTB did not
induce antibody responses significantly higher than those of
nPsaA without CTB. ePsaA mixed with CT or CTB also in-
duced more prominent immune responses than those of ePsaA
without CT or CTB. Although CTB is reportedly a poorer
adjuvant than CT (46), there was no significant difference in
antibody levels between ePsaA-CT and ePsaA-CTB.
Mucosal immune responses induced by coencapsulated an-
tigens (rPsaA and CTB) were higher than those induced by
mixing singly encapsulated rPsaA and CTB. The higher the
CTB content in the coencapsulated microsphere, the higher
the mucosal IgA response was. On the other hand, systemic
IgG and IgM levels were inversely proportional to the CTB
content in coencapsulated microspheres. Although we do not
know the exact mechanism, protective immunity was closely
related to serum IgG levels and inversely related to mucosal
IgA levels.
The immune exclusion and elimination at the mucosal sur-
faces by secretory IgA is crucial in preventing pneumococcal
bacteremia (41). In addition, it has been suggested that the
most important factor contributing to protection might be the
specific serum IgG levels for the prevention of septicemia (3).
Although the levels of antibodies that correlate with protection
against pneumococcal disease have not been clearly defined,
serum antibody responses and their opsonophagocytic activity
represent the major defense mechanism of the host against
pneumococcal infection (2). It seems that nasal immunization
would have been a preferred route of immunization, since
nasal immunization typically requires less antigen and adjuvant
than gastric immunization for the induction of both systemic
and mucosal immune responses. It also seems that nasal im-
munization may induce better protection against a challenge
administered via the nasal route. In a previous study, we com-
pared vaccine efficacies after introduction by the intranasal or
oral route (40). We found that lung clearance was better in the
group of mice immunized nasally than in those immunized
orally. Although regurgitated antigen might prime immune
cells in nose-associated lymphatic tissue (NALT), pneumococ-
cal septicemia was profoundly inhibited only in the group of
mice immunized orally. Nonetheless, we could not determine
which route is better. Taken together, these results indicate
that pneumococcal vaccines should be carefully analyzed in
terms of protective immunity by using mice immunized orally
as well as intranasally.
Following oral immunization with various antigens, protec-
tion was evaluated by intranasal challenge with various S. pneu-
moniae serotypes, i.e., types 19F, 4, 6B, 14, and 23F. The
numbers of pneumococci in the lungs and blood of mice im-
munized with e(PsaA-CTB)1 were profoundly reduced com-
pared to the control.
In summary, our data suggest that oral immunization with
rPsaA coencapsulated with CTB elicits specific antibody re-
sponses and provides cross-protective immunity against vari-
ous serotypes of pneumococci. They imply that oral vaccina-
tion with e(rPsaA-CTB) might be useful in populations with
relatively higher mucosal immunocompetency than systemic
immunocompetency, such as children under 2 years of age, the
elderly, and AIDS patients.
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